7498 Results (Page 237 of 300)
Pharmaceuticals Markets Research Reports
Brazil Diabetes Drugs Market Analysis
The Brazil diabetes drugs market size was valued at $1.54 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.1% from 2022 to 2030 and will reach $2.67 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The Brazil diabetes drug market will grow because the growing aging population, as the population ages, the incidence of diabetes is expected to increase, creating a greater demand for diabetes drugs. The key market players are Ache Laboratorios Farmaceuticos (BRA), Biolab Sanus Farmaceutica (BRA), Cristália Produtos Químicos (BRA), EMS Sigma Pharma (BRA)Boehringer Ingelheim, and others.
Australia Diabetes Drugs Market Analysis
The Australia diabetes drugs market size was valued at $0.74 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.6% from 2022 to 2030 and will reach $1.33 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The Australia diabetes drug market will grow because of the high prevalence of diabetes in the country, which creates a significant demand for medications to manage the disease. The key market players are CSL Limited, AstraZeneca, Novo Nordisk, Sanofi, and others.
Africa Diabetes Drugs Market Analysis
The Africa diabetes drugs market size was valued at $926.7 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.6% from 2022 to 2030 and will reach $1665 Mn in 2030. The market is segmented by drug type, application, and distribution channel. The African diabetes drug market will grow because the increasing prevalence of NCDs in Africa has contributed to the increasing prevalence of diabetes. The key market players are Johnson & Johnson, Novo Nordisk, Novartis, Merck, Eli Lilly and Company, and others.
Middle East Anti-Depressants Drugs Market Analysis
The Middle East Anti-Depressants drugs market size was valued at $3.12 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 5.9% from 2022 to 2030 and will reach $4.64 Bn in 2030. The market is segmented by drug class, indication, route of administration, end-user, and distribution channel. The Middle East Anti-Depressants drug market will grow because Depression is a common mental health disorder in the Middle East, affecting a significant portion of the population. The key market players are GlaxoSmithKline plc (GBR), AstraZeneca (GBR), Mallinckrodt (GBR), Novartis AG, and others.
Germany Alexipharmic Drugs Market Analysis
Germany's Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 2.90% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The Germany Alexipharmic Drugs market will grow because of growing awareness in Germany about the risks of poisoning and the importance of having quick access to antidotes in case of an emergency. The key market players are Merck KGaA (DEU), CSL Behring (DEU), Grifols Deutschland (DEU), Wockhardt GmbH (DEU), B. Braun Melsungen AG (DEU), and others.
Europe Alexipharmic Drugs Market Analysis
Europe's Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 3.44% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The Europe Alexipharmic Drugs market will grow because of the rising prevalence of various forms of chronic conditions and overdosing on prescription medications. The key market players are Bausch Health Companies Inc (Canada), Ethypharm S. A. (France), Fresenius SE & Co. KGaA (Fresenius Kabi) (Germany), Alkermes, Inc. (Ireland), Mylan N.V. (US), and others.
China Alexipharmic Drugs Market Analysis
China's Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 6.20% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The China Alexipharmic Drugs market will grow because the Chinese government and healthcare providers are increasing their efforts to raise public awareness about poisoning and the availability of antidotes. The key market players are Beijing Kawin Technology Share-Holding (CHN), Yino Pharma Limited (CHN), and others.
Australia Alexipharmic Drugs Market Analysis
Australia's Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 6.20% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The rising incidence of poisonings due to accidental or intentional exposure to toxins is driving the demand for alexipharmic drugs in Australia. The key market players are CSL Behring, Hospira, Mylan, Phebra (AUS), and others.
APAC Alexipharmic Drugs Market Analysis
The APAC Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 5.97% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The APAC Alexipharmic Drugs market will grow because chronic conditions have been increasing among women, adults aged elderly population, and those living in rural areas. The key market players are CSL Limited (AUS), Otsuka Pharmaceutical (JPN), SGPharma Pvt. Ltd. (India), Sandoz International, and others.
Vietnam Oncology Drugs Market Analysis
By 2030, it is anticipated that the Vietnam oncology drugs market will reach a value of $xx Mn from $982.2 Mn in 2022, growing at a CAGR of xx% during 2022-30. The oncology drugs market in Vietnam is dominated by a few domestic pharmaceutical companies such as Vimedimex Medi-Pharma, OPC Pharmaceutical, and Hanoi Pharmaceutical. The oncology market in Vietnam is segmented into different therapeutic areas and different treatment types. The major factors affecting the Vietnam oncology drugs market are the increasing disease burden of non-communicable diseases like cancer and the lack of healthcare facilities for cancer treatment in most areas of Vietnam.
Netherlands Oncology Drugs Market Analysis
By 2030, it is anticipated that the Netherlands oncology drugs market will reach a value of $xx Mn from $510.74 Mn in 2022, growing at a CAGR of xx% during 2022-30. The oncology drugs market in the Netherlands is dominated by a few domestic pharmaceutical companies such as Cristal Therapeutics, ABL Europe, and Synthon. The oncology market in the Netherlands is segmented into different therapeutic areas and different treatment types. The major factors affecting the Netherlands oncology drugs market are the increasing disease burden of non-communicable diseases like cancer and the lack of healthcare facilities for cancer treatment in most of the areas of the Netherlands.
UAE Anemia Drugs Market Analysis
The UAE Anemia drugs market was valued at $80 Mn in 2022 and is estimated to expand at a CAGR of 9.9% from 2022-30 and will reach $170 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Life Pharma, Neo Pharma, New Bridge Pharmaceuticals, Sahara pharmaceutical, GlaxoSmithKline, GlycoMimetics, and Amgen among others.
Japan Anemia Drugs Market Analysis
Japan's Anemia drugs market was valued at $993 Mn in 2022 and is estimated to expand at a CAGR of 9.40% from 2022-30 and will reach $2038 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Pfizer, Astellas Pharma, Takeda Pharmaceutical, Daiichi Sankyo Company, Chugai Pharmaceutical, Otsuka Holdings, Roche, and GSK among others.
Canada Anemia Drugs Market Analysis
Canada's Anemia drugs market was valued at $1.28 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 8.9% from 2022 to 2030 and will reach $2.53 Bn in 2030. One of the main reasons propelling the growth of this market is introduction of newer technologies, aging population. The market is segmented by type, drug and distribution channel. Some key players in this market are, Amgen, Roche, Takeda Pharmaceutical, Sanofi, and Novartis among others.
APAC Anemia Drugs Market Analysis
The APAC Anemia drugs market was valued at $3.36 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 10.17% from 2022 to 2030 and will reach $7.28 Bn in 2030. One of the main reasons propelling the growth of this market is the rising prevalence of chronic kidney disease and the aging population. The market is segmented by type, drug, and distribution channel. Some key players in this market are Amgen, Bayer AG, Takeda Pharmaceutical, GlaxoSmithKline, Johnson, and Johnson, Pfizer, and Novartis.
UK Alzheimer’s Disease Drugs Market Analysis
The UK Alzheimer’s disease drugs market was valued at $401 Mn in 2022 and is estimated to expand at a CAGR of 6.42% from 2022-30 and will reach $660 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are AbbVie, AstraZeneca, Accord Healthcare, Aesica Queenborough, Allen & Hanburys, Biogen, Daiichi Sankyo Company, Eisai Co., Eli Lilly and Company, Johnson and Johnson, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, Ono Pharmaceutical Co., Pfizer and Teva Pharmaceutical among others.
UAE Alzheimer’s Disease Drugs Market Analysis
UAE Alzheimer’s Disease Drugs market was valued at $77 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 9.42% from 2022 to 2030 and will reach $158 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Julphar, Lundbeck, Eisai Co., Eli Lilly and Company, Johnson and Johnson, H. Lundbeck A/S, Roche, Merck & Co., Novartis, Pfizer, and Teva Pharmaceutical among others.
UK Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the UK infectious disease therapeutics market will reach a value of $3.75 Bn from $3.12 Bn in 2022, growing at a CAGR of 2.4% during 2022-2030. Infectious Disease Therapeutics in the UK is dominated by a few domestic pharmaceutical companies such as GlaxoSmithKline, Faron Pharmaceuticals and Emergent BioSolutions. The infectious disease therapeutics market in the UK is segmented into different therapeutic areas and different treatment types. The major factors affecting the UK infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the lack of healthcare funding for infectious disease treatment in various areas of the UK.
UAE Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the UAE infectious disease therapeutics market will reach a value of $909.4 Mn from $599.35 Mn in 2022, growing at a CAGR of 5.4% during 2022-2030. The Infectious Disease Therapeutics in UAE is dominated by a few domestic pharmaceutical companies such as Medpharma, Julphar and Neopharma. The Infectious Disease Therapeutics market in UAE is segmented into different therapeutic areas and different diseases type. The major factors affecting the UAE infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the amount of healthcare funding for infectious diseases treatment in various the areas of UAE.
Turkey Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the Turkey infectious disease therapeutics market will reach a value of $1400 Mn from $958.96 Mn in 2022, growing at a CAGR of 4.9% during 2022-2030. Infectious Disease Therapeutics in Turkey is dominated by a few domestic pharmaceutical companies such as Abdi İbrahim, Deva Holding and Nobel İlaç. The Infectious Disease Therapeutics market in Turkey is segmented into different therapeutic areas and different diseases type. The major factors affecting the Turkey infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, COVID-19, and the amount of healthcare funding for infectious diseases treatment in various areas of Turkey.
India Alzheimer’s Disease Drugs Market Analysis
The India Alzheimer’s disease drugs market was valued at $280 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 11.42% from 2022 to 2030 and will reach $666 Mn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Sun Pharmaceutical Industries, Cipla, Dr. Reddy's Laboratories, Torrent Pharmaceuticals, Alkem Laboratories., Eli Lilly and Company, Johnson and Johnson, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, Pfizer.
Spain Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the Spain infectious disease therapeutics market will reach a value of $3.01 Bn from $2.31 Bn in 2022, growing at a CAGR of 2.6% during 2022-2030. Infectious Disease Therapeutics in Spain is dominated by a few domestic pharmaceutical companies such as Grifols, AB-Biotics and Zendal. The Infectious Disease Therapeutics market in Spain is segmented into different therapeutic areas and different diseases type. The major factors affecting the Spain infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, and COVID-19 and the lack of healthcare funding for infectious diseases treatment in various of areas of Spain.
Global Alzheimer’s Disease Drugs Market Analysis
Global Alzheimer’s disease drugs market was valued at $15.42 Bn in 2022 and is estimated to expand at a CAGR of 8.42% from 2022-30 and will reach $29.44 Bn in 2030. One of the main reasons propelling the growth of this market is the introduction of newer technologies, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are AbbVie, AstraZeneca, Biogen, Daiichi Sankyo Company, Eisai Co., Eli Lilly and Company, Johnson and Johnson, H. Lundbeck A/S, F. Hoffmann-La Roche AG, Merck & Co., Novartis AG, Ono Pharmaceutical Co., Pfizer and Teva Pharmaceutical among others.
South Africa Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the South Africa infectious disease therapeutics market will reach a value of $1203 Mn from $779.2 Mn in 2022, growing at a CAGR of 5.6% during 2022-2030. The Infectious Disease Therapeutics in South Africa is dominated by a few domestic pharmaceutical companies such as Biovac, Adcock Ingram and Aspen Pharmacare. The Infectious Disease Therapeutics market in South Africa is segmented into different therapeutic areas and different diseases type. The major factors affecting the South African infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, COVID-19, and the amount of healthcare funding for infectious diseases treatment in various areas of South Africa.
Poland Infectious Disease Therapeutics Market Analysis
By 2030, it is anticipated that the Poland infectious disease therapeutics market will reach a value of $1012 Mn from $695 Mn in 2022, growing at a CAGR of 4.8% during 2022-2030. Infectious Disease Therapeutics in Poland is dominated by a few domestic pharmaceutical companies such as Polpharma Group, Selvita and Adamed Group. The Infectious Disease Therapeutics market in Poland is segmented into different therapeutic areas and different diseases type. The major factors affecting the Poland infectious disease therapeutics market are the increasing disease burden of communicable diseases like TB, hepatitis, COVID-19, and the amount of healthcare funding for infectious diseases treatment in various areas of Poland.
